No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin
Authors:
- 26 August 2010
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 19 (10) , 1135-1145
Abstract
(2010). No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opinion on Investigational Drugs: Vol. 19, No. 10, pp. 1135-1145. doi: 10.1517/13543784.2010.509342Keywords
This publication has 23 references indexed in Scilit:
- Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEuropean Heart Journal, 2010
- Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.The American Journal of Cardiology, 2009
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with DyslipidemiaThe American Journal of Cardiology, 2008
- Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClinical Pharmacology & Therapeutics, 2006
- Relation Between On-Treatment Increments in Serum High-Density Lipoprotein Cholesterol Levels and Cardiac Mortality in Patients With Coronary Heart Disease (from the Bezafibrate Infarction Prevention Trial)The American Journal of Cardiology, 2006
- Benefits of Niacin in Patients With Versus Without the Metabolic Syndrome and Healed Myocardial Infarction (from the Coronary Drug Project)The American Journal of Cardiology, 2006
- Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and WomenCirculation, 2004
- Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in HumansCirculation, 2002
- Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary EventsJAMA, 2001
- Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene MutationNew England Journal of Medicine, 1990